RxDoctor Payments Data

Cecile Becker, MD

Neurology · Springfield, ILNPI 1750493540

Payments from drug & device makers

$54,953in general payments, 2019–2025

Across 726 payments — averaging $75.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$29K
  • AbbVie$19K
  • Teva Pharmaceuticals USA, Inc.$1K
  • AstraZeneca$725
  • Biohaven Pharmaceuticals, Inc.$673
  • Bristol Myers Squibb$642
  • plus $4K from 33 others
$52,075in research payments, 2019–2025

Across 2 payments — averaging $26,038 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$52K

What the payments were for

  • Speaking & faculty fees$13,25052%
  • Travel & lodging$1,2345%
  • Food & beverage$10,71742%
  • Education$5202%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$54,953 in reported general payments places this provider in the 85th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois

Medicare billing

Part B allowed, 2024
$999,184
Medicare patients
593
Services billed
50,135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SolirisEculizumab14$734,737
BetaseronInterferon Beta-1b14$131,407
Teriflunomide13$76,479
BotoxOnabotulinumtoxina46$70,983
NuplazidPimavanserin Tartrate12$59,940
BriviactBrivaracetam28$59,301
Nurtec OdtRimegepant Sulfate30$51,530
RytaryCarbidopa/Levodopa34$33,599
Lacosamide136$31,151
NourianzIstradefylline12$22,202
Pregabalin159$21,548
Ajovy AutoinjectorFremanezumab-Vfrm22$18,753
Aimovig AutoinjectorErenumab-Aooe19$18,480
UbrelvyUbrogepant19$18,170
Entacapone64$14,409

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSoliris$725$734,73714 claims
AbbVieBotox, Ubrelvy, Qulipta$18,578$102,16176 claims
Acadia Pharmaceuticals IncNuplazid$306$59,94012 claims
UCB, Inc.Briviact$468$59,30128 claims
PfizerNurtec Odt$38$51,53030 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$19$36,78171 claims
Kyowa Kirin, Inc.Nourianz$84$22,20212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 790 neurology providers in Illinois.

Other neurology in Springfield

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →